Final Exam Pcol2 Mw 8:30-10am

50 Questions | Total Attempts: 33

SettingsSettingsSettings
Please wait...
Final Exam Pcol2 Mw 8:30-10am

.


Questions and Answers
  • 1. 
    Laboratory test used to monitor the anticoagulant effect of warfarin which is prolonged when drug effect is adequate.
    • A. 

      Activated Partial Thromboplastin time (aPTT) test

    • B. 

      Antithrombin III

    • C. 

      Prothrombin time (PT) test

    • D. 

      Glycoprotein IIb/IIIa

  • 2. 
    An endogenous anticlotting protein that irreversibly inactivates thrombin and factor Xa.
    • A. 

      Heparin-induced Thrombocytopenia

    • B. 

      Antithrombin III

    • C. 

      Clotting cascade

    • D. 

      LMW heparins

  • 3. 
    Fractionated preparations of heparin of molecular weight 2000-6000
    • A. 

      Heparin-induced Thrombocytopenia

    • B. 

      Antithrombin III

    • C. 

      Glycoprotein IIb/IIIa

    • D. 

      LMW heparins

  • 4. 
    Its enzymatic action is markedly accelerated by the heparins
    • A. 

      Clotting cascade

    • B. 

      Glycoprotein IIb/IIIa

    • C. 

      Antithrombin III

    • D. 

      Heparin-induced Thrombocytopenia

  • 5. 
    Laboratory test used to monitor the anticoagulant effect of unfractionated heparin and direct thrombin inhibitors which is prolonged when drug effect is adequate
    • A. 

      Clotting cascade

    • B. 

      Activated Partial Thromboplastin time (aPTT) test

    • C. 

      Prothrombin time (PT) test

    • D. 

      FTIR

  • 6. 
    Unfractionated heparin has a molecular weight range of 5000-30000
    • A. 

      Glycoprotein IIb/IIIa

    • B. 

      Clotting cascade

    • C. 

      Prothrombin time (PT) test

    • D. 

      LMW heparins

  • 7. 
    System of serine proteases and substrates in the blood that provides rapid generation of clotting factors in response to blood vessel damage
    • A. 

      Clotting cascade

    • B. 

      Heparin-induced Thrombocytopenia

    • C. 

      LMW heparins

    • D. 

      Prothrombin time (PT) test

  • 8. 
    A protein complex on the surface of platelets
    • A. 

      Clotting cascade

    • B. 

      LMW heparins

    • C. 

      Heparin-induced Thrombocytopenia

    • D. 

      Glycoprotein IIb/IIIa

  • 9. 
    When activated, it aggregates platelets primarily by binding to fibrin
    • A. 

      LMW heparins

    • B. 

      Heparin-induced Thrombocytopenia

    • C. 

      Glycoprotein IIb/IIIa

    • D. 

      Clotting cascade

  • 10. 
    A hypercoagulable state plus thrombocytopenia that occurs in a small number of individuals treated with unfractionated heparin
    • A. 

      Prothrombin time (PT) test

    • B. 

      Glycoprotein IIb/IIIa

    • C. 

      Heparin-induced Thrombocytopenia

    • D. 

      LMW heparins

  • 11. 
    It is activated by endogenous factors such as thromboxane A2, ADP and serotonin which initiates a signaling cascade
    • A. 

      Glycoprotein IIb/IIIa

    • B. 

      Antithrombin III

    • C. 

      LMW heparins

    • D. 

      Glycoprotein IIb/IVa

  • 12. 
    Site of Action for Heparin
    • A. 

      Small Intestines

    • B. 

      Skin

    • C. 

      Blood

    • D. 

      Liver

  • 13. 
    Site of Action for Warfarin
    • A. 

      Small Intestines

    • B. 

      Blood

    • C. 

      Skin

    • D. 

      Liver

  • 14. 
    MOA of Heparin
    • A. 

      Activates antithrombin III

    • B. 

      Impairs post-translational modification factors II, VII, IX and X

    • C. 

      Both

    • D. 

      None of the answers

  • 15. 
    Antidote for Heparin toxicity or overdose
    • A. 

      Protamine for unfractionated heparin

    • B. 

      Vitamin K

    • C. 

      Plasma

    • D. 

      Prothrombin complex concentrates

  • 16. 
    Can Heparin be used for pregnant patients?
    • A. 

      Yes

    • B. 

      No

    • C. 

      Option 3

    • D. 

      Option 4

  • 17. 
    Which clotting factor/s is/are inhibited by Heparin?
    • A. 

      IX

    • B. 

      XIa

    • C. 

      II

    • D. 

      X

  • 18. 
    Which clotting factor/s is/are inhibited by Oral Anticoagulant drugs?
    • A. 

      XIa

    • B. 

      VIIIa

    • C. 

      X

    • D. 

      Va

  • 19. 
    Clinical uses of Heparin
    • A. 

      DVT

    • B. 

      Pulmonary embolism

    • C. 

      Acute MI

    • D. 

      All of the answers

  • 20. 
    Which statement is TRUE? (You can tick more than once)
    • A. 

      Heparin is the drug of choice when an anticoagulant must be used in pregnancy.

    • B. 

      Heparin does not cross the placental barrier.

    • C. 

      The action of Heparin is monitored by PT.

    • D. 

      Option 4

  • 21. 
    Which statement/s is/are TRUE about Rivaroxaban and Apixaban? (you can tick more than once)
    • A. 

      They are oral Xa Inhibitors

    • B. 

      Have a rapid onset of action and shorter half-lives than warfarin

    • C. 

      They require monitoring

    • D. 

      They undergo cytochrome P450-dependent and cytochrome P450-independent elimination.

    • E. 

      Their MOA is to directly bind to and inhibit both free factor Xa and factor Xa bound in the clotting complex

  • 22. 
    This drug inhibits vitamin K epoxide reductase.
    • A. 

      Warfarin

    • B. 

      Heparin

    • C. 

      Xarelto

    • D. 

      Eliquis

  • 23. 
    Which statement is true about Warfarin?
    • A. 

      Has a narrow therapeutic window

    • B. 

      Antidote is Protamine

    • C. 

      Can inhibit Xa Factors

    • D. 

      The effect of warfarin is monitored by aPTT test

  • 24. 
    Which statement/s is/are TRUE about Thrombolytic Agents? (you can tick more than once)
    • A. 

      It either comes in the form of tPA or a protein synthesized by streptococci.

    • B. 

      All are given in IV

    • C. 

      TPA is an enzyme that directly converts plasmin to plasminogen

    • D. 

      Alteplase is normal human plasminogen activator while Reteplase is a mutated form of human tPA with similar effects but a slightly slower onset of action and longer duration of action.

    • E. 

      The major application of Thrombolytic agents is an alternative to percutaneous coronary angioplasty in the emergency treatment of coronary artery thrombosis.

  • 25. 
    Which statement is TRUE on the clinical use of Thrombolytics?
    • A. 

      Cerebral hemorrhage must be positively ruled out before each use.

    • B. 

      It is not indicated for sever pulmonary embolism.

    • C. 

      Under ideal conditions such as treatment within 24hrs, these agents can promptly recanalize the occluded coronary vessel.

    • D. 

      Very prompt use of tPA, such as within 6hrs of the 1st symptoms of ischemic stroke, is associated with a significantly better clinical outcome.

Back to Top Back to top